Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: Effect on response to efavirenz-based therapy in an urban observational cohort

Journal of Infectious Diseases

Volumn 189, Issue 9, 2004, Pages 1688-1695

  Tozzi, Valerio ^a   Zaccarelli, Mauro ^a   Narciso, Pasquala ^a   Trotta, Maria Paola ^a   Caccherini Silberstein, Francesca ^a   Da Longis, Patrizio ^a   D'Offizi, Giampiero ^a   Forbici, Federica ^a   D'Arrigo, Roberta ^a   Boumis, Evangelo ^a   Bellagamba, Rita ^a   Bonfigli, Sandro ^a   Carvalli, Chiarina ^a   Antinori, Andrea ^a   Perno, Carlo Fedarico ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE REPRESSION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS ACTIVATION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; OXAZINES; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; URBAN POPULATION; VIRAL LOAD;

EID: 2442419529     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/382960     Document Type: Article

References (20)

1. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267:988-93.
2. Rittinger K, Divita G, Goody RS. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci USA 1995; 92:8046-9.
3. Whitcomb J, Deeks S, Huang W, et al. Reduced susceptibility to NRTI is associated with NNRTI hypersensitivity in virus from HIV-1 infected patients [abstract 234]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2000:145.
4. Whitcomb JM, Huang W, Limoli K, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 2002; 16:F41-7.
5. Hirsch MS, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendation of an International AIDS Society - USA panel. JAMA 2000; 283:2417-26.
6. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as a part of treatment management: recommendations for the European setting. AIDS 2001; 15:309-20.
7. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www.hivatis.org. Accessed 21 July 2003.
8. Shulman N, Zolopa AR, Passaro D, et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001; 15:1125-32.
9. Mellors J, Vaida F, Bennett K, Hellmann N, DeGruttola V, Hamme S. Efavirenz hypersusceptibility improves virologic response to multidrug salvage regimens in ACTG 398 [abstract 45]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle) Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:69.
10. Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitors hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16:F33-40.
11. Walmsley SL, Kelly DV, Tseng AL, Humar A, Harrigan PR. Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy. AIDS 2001; 15:1581-4.
12. Wei X, Liang C, Gotte M, Wainberg MA. Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology 2003; 311:202-12.
13. Harrigan PR, Kinghorn I, Bloor S, et al. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 1996; 70:5930-4.
14. Ross L, Scarsella A, Raffanti S, et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res Hum Retroviruses 2001; 17:1107-15.
15. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
16. Ledergeber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863-8.
17. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353:2195-9.
18. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14:F83-93.
19. Tural C, Ruiz L, Holtzer C, et al. The clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-18.
20. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-79.